US6506766B1
(en)
*
|
1998-02-13 |
2003-01-14 |
Abbott Laboratories |
Glucocortiocoid-selective antinflammatory agents
|
US7026484B2
(en)
*
|
2001-02-23 |
2006-04-11 |
Ligand Pharmaceuticals Incorporated |
Tricyclic androgen receptor modulator compounds and methods
|
US6518430B1
(en)
*
|
2001-09-21 |
2003-02-11 |
Abbott Laboratories |
Process for the preparation of 5-(substituted)-10-methoxy-2,2,4-trimethyl-2,5-dihydro-1H-chromeno[3,4-F]quinolines and derivatives thereof
|
AU2003202216A1
(en)
*
|
2002-01-14 |
2003-07-30 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Glucocorticoid mimetics, methods of making them, pharmaceutical formulations containing them and uses thereof
|
EP1490317A1
(en)
*
|
2002-03-26 |
2004-12-29 |
Boehringer Ingelheim Pharmaceuticals Inc. |
Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
|
DK1490062T3
(da)
*
|
2002-03-26 |
2008-04-28 |
Boehringer Ingelheim Pharma |
Glukokortikoidmimetika, fremgangsmåder til fremstilling deraf, farmaceutiske sammensætninger og anvendelser deraf
|
WO2003086294A2
(en)
*
|
2002-04-11 |
2003-10-23 |
Merck & Co., Inc. |
1h-benzo[f]indazol-5-yl derivatives as selective glucocorticoid receptor modulators
|
US7186864B2
(en)
|
2002-05-29 |
2007-03-06 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
|
US7074806B2
(en)
*
|
2002-06-06 |
2006-07-11 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
|
GB2389530B
(en)
|
2002-06-14 |
2007-01-10 |
Cipla Ltd |
Pharmaceutical compositions
|
US6858627B2
(en)
*
|
2002-08-21 |
2005-02-22 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
|
BR0313923A
(pt)
*
|
2002-08-29 |
2005-07-12 |
Boehringer Ingelheim Pharma |
Derivados de 3-(sulfonamidoetil)-indol para uso como miméticos de glicocorticóide no tratamento de doenças inflamatórias, alérgicas e proliferativas
|
US20040220153A1
(en)
*
|
2002-09-24 |
2004-11-04 |
Jost-Price Edward Roydon |
Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
|
CL2003001544A1
(es)
*
|
2002-10-11 |
2005-01-07 |
Ligand Pharm Inc |
Compuestos derivados de 5-cicloalquenil-5h-cromeno[3,4-f]quinolina de formula i, moduladores selectivos del receptor de progesterona; composicion farmaceutica; y su uso en el tratamiento de sangrado uterino disfuncional, dismenorrea, endometriosis, l
|
DE20301728U1
(de)
*
|
2002-10-11 |
2004-03-11 |
Ligand Pharmaceuticals, Inc., San Diego |
5-substituierte 7,9-Difluor-5H-Chromeno(3,4-f) -Chinolin-Verbindungen als selektive Progesteronrezeptormodulator-Verbindungen
|
AR040783A1
(es)
*
|
2002-10-11 |
2005-04-20 |
Ligand Pharm Inc |
5-(1',1'-cicloaquil/alquenil) metiliden-1,2 -dihidro-5-h-cromeno [3,4- f] quiinolinas como compuestos moduladores selectivos de receptores de progesterona
|
WO2004063163A1
(en)
*
|
2003-01-03 |
2004-07-29 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
1-propanol and 1-propylamine derivatives and their use as glucocorticoid ligands
|
US20040224992A1
(en)
*
|
2003-02-27 |
2004-11-11 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
|
US20070088042A1
(en)
*
|
2004-09-09 |
2007-04-19 |
Meissner Robert S |
Fluorinated 4-azasteroid derivatives as androgen receptor modulators
|
US7235662B2
(en)
|
2003-06-11 |
2007-06-26 |
Bristol-Myers Squibb Company |
Modulators of the glucocorticoid receptor and method
|
GB0316290D0
(en)
|
2003-07-11 |
2003-08-13 |
Glaxo Group Ltd |
Novel compounds
|
US8097606B2
(en)
|
2003-07-23 |
2012-01-17 |
Corcept Therapeutics, Inc. |
Antiglucocorticoids for the treatment of catatonia
|
CA2536349A1
(en)
|
2003-08-22 |
2005-03-03 |
Ligand Pharmaceuticals Incorporated |
6-cycloamino-2-quinolinone derivatives as androgen receptor modulator compounds
|
UY28526A1
(es)
|
2003-09-24 |
2005-04-29 |
Boehringer Ingelheim Pharma |
Miméticos de glucocorticoides, métodos de preparación composiciones farmacéuticas y usos de los mismos
|
TW200517114A
(en)
|
2003-10-15 |
2005-06-01 |
Combinatorx Inc |
Methods and reagents for the treatment of immunoinflammatory disorders
|
WO2005040145A1
(en)
*
|
2003-10-16 |
2005-05-06 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Stereoselective synthesis of certain trifluoromethyl-substituted alcohols
|
ATE497763T1
(de)
|
2003-11-21 |
2011-02-15 |
Zalicus Inc |
Verfahren und reagenzien zur behandlung von entzündlichen erkrankungen
|
WO2005082909A1
(en)
*
|
2004-02-25 |
2005-09-09 |
Ligand Pharmaceuticals Incorporated |
Glucocorticoid receptor modulator compounds and methods- utility
|
WO2005090282A1
(en)
|
2004-03-12 |
2005-09-29 |
Ligand Pharmaceuticals Incorporated |
Androgen receptor modulator compounds and methods
|
US7795272B2
(en)
*
|
2004-03-13 |
2010-09-14 |
Boehringer Ingelheim Pharmaceutical, Inc. |
Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof
|
PE20060272A1
(es)
|
2004-05-24 |
2006-05-22 |
Glaxo Group Ltd |
(2r,3r,4s,5r,2'r,3'r,4's,5's)-2,2'-{trans-1,4-ciclohexanodiilbis-[imino(2-{[2-(1-metil-1h-imidazol-4-il)etil]amino}-9h-purin-6,9-diil)]}bis[5-(2-etil-2h-tetrazol-5-il)tetrahidro-3,4-furanodiol] como agonista a2a
|
TWI307630B
(en)
|
2004-07-01 |
2009-03-21 |
Glaxo Group Ltd |
Immunoglobulins
|
JP2008525525A
(ja)
*
|
2004-12-27 |
2008-07-17 |
ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド |
グルココルチコイドミメティクス、その製法、医薬組成物及び使用
|
ATE517908T1
(de)
|
2005-01-10 |
2011-08-15 |
Glaxo Group Ltd |
Androstan-17-alpha-carbonat-derivate zur verwendung bei der behandlung allergischer und entzündlicher zustände
|
PE20061351A1
(es)
|
2005-03-25 |
2007-01-14 |
Glaxo Group Ltd |
COMPUESTOS 8H-PIRIDO[2,3-d]PIRIMIDIN-7-ONA 2,4,8-TRISUSTITUIDOS COMO INHIBIDORES DE LA QUINASA CSBP/RK/p38
|
TW200724142A
(en)
|
2005-03-25 |
2007-07-01 |
Glaxo Group Ltd |
Novel compounds
|
CA2598216C
(en)
|
2005-06-17 |
2014-04-08 |
Ligand Pharmaceuticals Incorporated |
Androgen receptor modulator compounds and methods
|
GB0514809D0
(en)
|
2005-07-19 |
2005-08-24 |
Glaxo Group Ltd |
Compounds
|
CN101355876B
(zh)
|
2005-11-09 |
2012-09-05 |
康宾纳特克斯公司 |
一种适用于眼部给药的组合物
|
TW200730498A
(en)
|
2005-12-20 |
2007-08-16 |
Glaxo Group Ltd |
Compounds
|
US8178573B2
(en)
|
2006-04-20 |
2012-05-15 |
Glaxo Group Limited |
Compounds
|
GB0611587D0
(en)
|
2006-06-12 |
2006-07-19 |
Glaxo Group Ltd |
Novel compounds
|
WO2008033466A2
(en)
*
|
2006-09-14 |
2008-03-20 |
Combinatorx (Singapore) Pre. Ltd. |
Compositions and methods for treatment of viral diseases
|
JP2010512331A
(ja)
*
|
2006-12-06 |
2010-04-22 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
グルココルチコイド模倣薬、それらの製造方法、医薬組成物、及びこれらの使用
|
AR065804A1
(es)
|
2007-03-23 |
2009-07-01 |
Smithkline Beecham Corp |
Compuesto de indol carboxamida, composicion farmaceutica que lo comprende y uso de dicho compuesto para preparar un medicamento
|
EP2285803A4
(en)
|
2008-05-23 |
2011-10-05 |
Amira Pharmaceuticals Inc |
Inhibitor of 5-Lipoxygenase Activating Protein
|
JP5502858B2
(ja)
|
2008-06-05 |
2014-05-28 |
グラクソ グループ リミテッド |
Pi3キナーゼの阻害剤として有用な4−カルボキサミドインダゾール誘導体
|
ATE552255T1
(de)
|
2008-06-05 |
2012-04-15 |
Glaxo Group Ltd |
4-aminoindazole
|
US8268859B2
(en)
*
|
2008-06-06 |
2012-09-18 |
Boehringer Ingelheim International Gmbh |
Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof
|
WO2010021681A2
(en)
*
|
2008-08-18 |
2010-02-25 |
Combinatorx (Singapore) Pte. Ltd. |
Compositions and methods for treatment of viral diseases
|
WO2010094643A1
(en)
|
2009-02-17 |
2010-08-26 |
Glaxo Group Limited |
Quinoline derivatives and their uses for rhinitis and urticaria
|
JP5656880B2
(ja)
|
2009-03-09 |
2015-01-21 |
グラクソ グループ リミテッドGlaxo Group Limited |
Pi3キナーゼの阻害剤としての4−オキサジアゾール−2−イル−インダゾール
|
WO2010102968A1
(en)
|
2009-03-10 |
2010-09-16 |
Glaxo Group Limited |
Indole derivatives as ikk2 inhibitors
|
WO2010106016A1
(en)
|
2009-03-17 |
2010-09-23 |
Glaxo Group Limited |
Pyrimidine derivatives used as itk inhibitors
|
CN102439151A
(zh)
|
2009-03-19 |
2012-05-02 |
默沙东公司 |
使用短干扰核酸(siNA)的RNA干扰介导的BTB和CNC同系物1,碱性亮氨酸拉链转录因子1(Bach1)基因表达的抑制
|
WO2010107957A2
(en)
|
2009-03-19 |
2010-09-23 |
Merck Sharp & Dohme Corp. |
RNA INTERFERENCE MEDIATED INHIBITION OF GATA BINDING PROTEIN 3 (GATA3) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
WO2010107952A2
(en)
|
2009-03-19 |
2010-09-23 |
Merck Sharp & Dohme Corp. |
RNA INTERFERENCE MEDIATED INHIBITION OF CONNECTIVE TISSUE GROWTH FACTOR (CTGF) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
EP2408458A1
(en)
|
2009-03-19 |
2012-01-25 |
Merck Sharp&Dohme Corp. |
RNA INTERFERENCE MEDIATED INHIBITION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 6 (STAT6) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
US20120022142A1
(en)
|
2009-03-27 |
2012-01-26 |
Merck Sharp & Dohme Corp. |
RNA Interference Mediated Inhibition of Signal Transducer and Activator of Transcription 1 (STAT1) Gene Expression Using Short Interfering Nucleic Acid (siNA)
|
US20120004281A1
(en)
|
2009-03-27 |
2012-01-05 |
Merck Sharp & Dohme Corp |
RNA Interference Mediated Inhibition of the Nerve Growth Factor Beta Chain (NGFB) Gene Expression Using Short Interfering Nucleic Acid (siNA)
|
WO2010111490A2
(en)
|
2009-03-27 |
2010-09-30 |
Merck Sharp & Dohme Corp. |
RNA INTERFERENCE MEDIATED INHIBITION OF THE THYMIC STROMAL LYMPHOPOIETIN (TSLP) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
JP2012521765A
(ja)
|
2009-03-27 |
2012-09-20 |
メルク・シャープ・エンド・ドーム・コーポレイション |
低分子干渉核酸(siNA)を用いた細胞内接着分子1(ICAM−1)遺伝子発現のRNA干渉媒介性阻害
|
WO2010111464A1
(en)
|
2009-03-27 |
2010-09-30 |
Merck Sharp & Dohme Corp. |
RNA INTERFERENCE MEDIATED INHIBITION OF APOPTOSIS SIGNAL-REGULATING KINASE 1 (ASK1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
EP2421834A1
(en)
|
2009-04-24 |
2012-02-29 |
Glaxo Group Limited |
Pyrazole and triazole carboxamides as crac channel inhibitors
|
EP2421835A1
(en)
|
2009-04-24 |
2012-02-29 |
Glaxo Group Limited |
N-pyrazolyl carboxamides as crac channel inhibitors
|
AU2010243613B2
(en)
|
2009-04-30 |
2015-05-07 |
Glaxo Group Limited |
Oxazole substituted indazoles as PI3-kinase inhibitors
|
WO2011067366A1
(en)
|
2009-12-03 |
2011-06-09 |
Glaxo Group Limited |
Indazole derivatives as pi 3 - kinase inhibitors
|
US20120245171A1
(en)
|
2009-12-03 |
2012-09-27 |
Glaxo Group Limited |
Benzpyrazole derivatives as inhibitors of pi3 kinases
|
US20120238559A1
(en)
|
2009-12-03 |
2012-09-20 |
Glaxo Group Limited |
Novel compounds
|
EP3020393B1
(en)
|
2009-12-16 |
2020-10-07 |
3M Innovative Properties Company |
Formulations and methods for controlling mdi particle size delivery
|
WO2011110575A1
(en)
|
2010-03-11 |
2011-09-15 |
Glaxo Group Limited |
Derivatives of 2-[2-(benzo- or pyrido-) thiazolylamino]-6-aminopyridine, useful in the treatment of respiratoric, allergic or inflammatory diseases
|
GB201007203D0
(en)
|
2010-04-29 |
2010-06-16 |
Glaxo Group Ltd |
Novel compounds
|
HUE026059T2
(en)
|
2010-09-08 |
2016-05-30 |
Glaxosmithkline Ip Dev Ltd |
N- [5- [4- (5 - {[(2R, 6S) -2,6-dimethyl-4-morpholinyl] methyl} -1,3-oxazol-2-yl) -1H-indazol-6-yl ] Polymorphs and salts of 2 - (methyloxy) -3-pyridinyl] methanesulfonamide
|
US9326987B2
(en)
|
2010-09-08 |
2016-05-03 |
Glaxo Group Limited |
Indazole derivatives for use in the treatment of influenza virus infection
|
WO2012035055A1
(en)
|
2010-09-17 |
2012-03-22 |
Glaxo Group Limited |
Novel compounds
|
EP2630126B1
(en)
|
2010-10-21 |
2015-01-07 |
Glaxo Group Limited |
Pyrazole compounds acting against allergic, immune and inflammatory conditions
|
EP2630127A1
(en)
|
2010-10-21 |
2013-08-28 |
Glaxo Group Limited |
Pyrazole compounds acting against allergic, inflammatory and immune disorders
|
GB201018124D0
(en)
|
2010-10-27 |
2010-12-08 |
Glaxo Group Ltd |
Polymorphs and salts
|
GB201104153D0
(en)
|
2011-03-11 |
2011-04-27 |
Glaxo Group Ltd |
Novel compounds
|
US20140005188A1
(en)
|
2011-03-11 |
2014-01-02 |
Glaxo Group Limited |
Pyrido[3,4-b]pyrazine derivatives as syk inhibitors
|
KR20160060100A
(ko)
|
2013-09-22 |
2016-05-27 |
칼리토르 사이언시즈, 엘엘씨 |
치환된 아미노피리미딘 화합물 및 이용 방법
|
AU2014336251A1
(en)
|
2013-10-17 |
2016-04-14 |
Glaxosmithkline Intellectual Property Development Limited |
PI3K inhibitor for treatment of respiratory disease
|
RU2016112268A
(ru)
|
2013-10-17 |
2017-11-22 |
Глаксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед |
Ингибитор PI3K для лечения респираторного заболевания
|
JP6517319B2
(ja)
|
2014-03-28 |
2019-05-22 |
キャリター・サイエンシーズ・リミテッド・ライアビリティ・カンパニーCalitor Sciences, Llc |
置換されたヘテロアリール化合物および使用方法
|
US20170100385A1
(en)
|
2014-05-12 |
2017-04-13 |
Glaxosmithkline Intellectual Property (No. 2) Limited |
Pharmaceutical compositions comprising danirixin for treating infectious diseases
|
EP3347097B1
(en)
|
2015-09-11 |
2021-02-24 |
Sunshine Lake Pharma Co., Ltd. |
Substituted aminopyrimidine derivatives as modulators of the kinases jak, flt3 and aurora
|
GB201602527D0
(en)
|
2016-02-12 |
2016-03-30 |
Glaxosmithkline Ip Dev Ltd |
Chemical compounds
|
US20190161480A1
(en)
|
2016-08-08 |
2019-05-30 |
Glaxosmithkline Intellectual Property Development Limited |
Chemical Compounds
|
GB201706102D0
(en)
|
2017-04-18 |
2017-05-31 |
Glaxosmithkline Ip Dev Ltd |
Chemical compounds
|
GB201712081D0
(en)
|
2017-07-27 |
2017-09-13 |
Glaxosmithkline Ip Dev Ltd |
Chemical compounds
|
US10683297B2
(en)
|
2017-11-19 |
2020-06-16 |
Calitor Sciences, Llc |
Substituted heteroaryl compounds and methods of use
|
AU2019209960B2
(en)
|
2018-01-20 |
2023-11-23 |
Sunshine Lake Pharma Co., Ltd. |
Substituted aminopyrimidine compounds and methods of use
|
CN108530402B
(zh)
*
|
2018-04-10 |
2020-06-26 |
浙江工业大学 |
一种(R)-3-丙基-γ-丁内酯的制备方法
|
WO2021191875A1
(en)
|
2020-03-26 |
2021-09-30 |
Glaxosmithkline Intellectual Property Development Limited |
Cathepsin inhibitors for preventing or treating viral infections
|